ReviewCureus2025
Neonatal Outcomes Following Elective Induction of Labor at 39 Weeks: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elective induction of labor (eIOL) at 39 weeks of gestation has gained prominence in obstetric practice, yet its impact on neonatal outcomes remains debated. This systematic review aimed to synthesize evidence on neonatal outcomes following eIOL at 39 weeks compared to expectant management, addressing critical knowledge gaps to inform clinical decision-making. Following PRISMA guidelines, a comprehensive search of PubMed, Scopus, Web of Science, and Embase identified 16 eligible studies. Inclusion criteria focused on low-risk pregnancies undergoing eIOL at 39 weeks, with neonatal outcomes as primary endpoints. Risk of bias was assessed using the Newcastle-Ottawa Scale for cohort studies and Cochrane RoB 2 for the RCT. Narrative synthesis was performed due to heterogeneity. Key findings demonstrated that eIOL at 39 weeks was associated with reduced cesarean delivery rates and lower perinatal mortality, without significant increases in adverse neonatal outcomes. However, subgroup analyses revealed variability: obese women benefited from reduced macrosomia and NICU admissions, while women with prior cesareans faced higher failed TOLAC rates. The RCT confirmed lower cesarean rates but no reduction in composite neonatal morbidity. eIOL at 39 weeks is a safe and effective strategy for reducing cesarean deliveries and perinatal mortality in low-risk populations, though benefits vary by subgroup. Shared decision-making, tailored to maternal characteristics, is essential. Future research should prioritize RCTs in high-risk populations and long-term neonatal follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.